Telix Pharmaceuticals agrees to acquire ITM Isotope for about $1.65B

Telix Pharmaceuticals (ASX:TLX) agreed to acquire Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis. After adjustments, ITM shareholders are expected to receive about $1.25 billion in Telix shares at $11.84 per share.